Market research
MAH0.F Mereo BioPharma Group plc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 685.01
- Dividend yield
- Not available
- Beta
- 0.3
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5894921072
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 685.01
- Dividend yield
- Not available
- Beta
- 0.3
About
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MAH0.F discussion.
5 years, 5 months ago
Mereo BioPharma Group plc is currently in a long term downtrend where the price is trading 0.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Finally, its free cash flow grew by 6.0% to $-9M since the same quarter in the previous year.
Based on the above factors, Mereo BioPharma Group plc gets an overall score of 2/5.